Talphera Inc(TLPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:40 AM ET (Korea 9/11 20:40)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.26 | Insider Own | 25.69% | Shs Outstand | 51.9M | Perf Week | 3.33% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | -5% | Insider Trans | 1.63% | Shs Float | 38.6M | Perf Month | -15.65% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.05 | Inst Own | 45.99% | Short Float | 1.34% | Perf Quarter | 53.41% |
| Income | -0.02B | P/S | - | EPS this Y | 41.18% | Inst Trans | 0.51% | Short Ratio | 1.62 | Perf Half Y | 38.32% |
| Sales | 0.00B | P/B | 4.47 | EPS next 5Y | 28.04% | ROA | -69.6% | Short Interest | 0.52M | Perf YTD | 8.77% |
| Book/sh | 0.28 | P/C | 3.77 | EPS past 3/5Y | - 48.69% | ROE | -143.36% | 52W High | -21.02% ($1.57) | Perf Year | 45.88% |
| Cash/sh | 0.33 | P/FCF | - | Sales past 3/5Y | - -65.11% | ROIC | -72.12% | 52W Low | 80.6% ($0.69) | Perf 3Y | 42.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.57% | Gross Margin | - | Volatility(W/M) | 2.25% 5.27% | Perf 5Y | -93.92% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -96.3% | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | -98.05% |
| Dividend Ex-Date | - | Quick Ratio | 4.29 | EPS Q/Q | 43.47% | Profit Margin | - | RSI (14) | 51.26 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.29 | Sales Q/Q | - | SMA20 | 2.69% ($1.21) | Beta | 0.67 | Target Price | $3.12 |
| Payout | - | Debt/Eq | 0.45 | Earnings | 2026/8/12 | SMA50 | -3.04% ($1.28) | Rel Volume | 0.68 | Prev Close | $1.22 |
| Employees | 12 | LT Debt/Eq | 0.45 | EPS/Sales Surpr. | 4% - | SMA200 | 21.21% ($1.02) | Avg Volume(3M) | 0.32M | Price | $1.24 |
| IPO | 2011/2/11 | Option/Short | Yes/Yes | Trades | 287 | Volume | 216,976 | Change | 1.64% |
Company
TLPH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A specialty pharmaceutical company developing Niyad (nafamostat formulation), an anticoagulant for patients undergoing continuous renal replacement therapy (CRRT) in the intensive care unit. Niyad is an FDA-designated drug candidate aimed at reducing bleeding risk compared with conventional heparin, and the company is currently running the Phase 3 NEPHRO CRRT clinical trial. Formerly AcelRx Pharmaceuticals, the company changed its name in 2024.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
TLPH has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +41.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +42.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 46.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $64M.
TLPH $64M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is TLPH?
TLPH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TLPH?
The market cap of TLPH is approximately $64M, ranking 4,821 within its sector.
What is the 52-week high and low for TLPH?
TLPH has recorded a 52-week high of $1.57 and a low of $0.69.
